



CENTER FOR MEDICARE

DATE: September 1, 2022

TO: Medicare Advantage Organizations and Medicare-Medicaid Plans

SUBJECT: Coverage of COVID-19 Monoclonal Antibody Products by Medicare Advantage Plans

During the COVID-19 public health emergency (PHE), [Medicare covers and pays for COVID-19 monoclonal antibody products and their administration](#) (when furnished consistent with their respective Emergency Use Authorizations) the same way it covers and pays for [COVID-19 vaccines](#). CMS finalized in the [Calendar Year \(CY\) 2022 Medicare Physician Fee Schedule Final Rule](#) that it will continue to pay for COVID-19 monoclonal antibodies under the Medicare Part B vaccine benefit through the end of the calendar year in which the PHE ends.

CMS reminds Medicare Advantage (MA) organizations and Medicare-Medicaid plans that they are required to pay for Part B benefits for their enrollees and cost sharing for a COVID-19 vaccine and its administration must not exceed the cost sharing in original Medicare (\$0). This includes coverage of [COVID-19 monoclonal antibody products and administration](#), without cost sharing, for beneficiaries enrolled in their MA plans through the end of the calendar year in which the PHE ends.

CMS notes that COVID-19 monoclonal antibody products were implicitly included in CMS' pandemic projection factors supporting the [2022](#) and [2023 Medicare Advantage benchmark rates](#). Once coverage and payment of COVID-19 monoclonal antibody products under the Medicare Part B vaccine benefit ends, MA plan coverage of Food and Drug Administration-approved monoclonal antibody products will be as a Part B drug/other biological product furnished incident to a physician's professional service.

For additional information about this policy and CMS's proposals for CY 2023, please see the [Calendar Year 2023 Physician Fee Schedule proposed rule](#).